Radiation recall myelitis following paclitaxel chemotherapy

The first reported case

Shearwood McClelland, Paul H. Cooper, Anupama K. Acheson, Jeremy Ciporen, Jerry Jaboin, Timur Mitin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Stereotactic body radiotherapy (SBRT) of the spine has become an increasingly utilized modality in the United States, most commonly for metastatic disease (McClelland et al., 2017). Spinal SBRT in patients with spinal instrumentation has been sparsely examined. We report a patient who developed myelitis following spinal SBRT to a region with existing hardware. Methods: A 55-year-old woman with Stage IV breast cancer developed a T4 vertebral body metastasis and underwent tumor debulking with posteriorly instrumented T3-T5 fusion. Postoperatively she proceeded with SBRT to the T3-T5 vertebral bodies, receiving 30 Gy in 6 Gy/fraction. Seven months later, she required paclitaxel chemotherapy (80 mg/m2 per cycle) for new liver metastases. Results: Eight months following spine SBRT, four weeks after having started chemotherapy she developed intractable back pain and right lower extremity numbness which improved upon receiving steroids for weekly chemotherapy; the numbness subsequently spread to her left leg. Thoracic spine MRI revealed a 1.7 cm ovoid focus of T4-T5 spinal cord enhancement with extensive surrounding cord edema extending superiorly to C6-C7, consistent with radiation myelitis. Hyperbaric oxygen moderately improved her symptoms; fortunately, she never developed motor symptomatology or bowel/bladder dysfunction. Thorough re-evaluation of the original thoracic spine SBRT plan revealed no deviations from the standard of care, nor did re-planning with alternate treatment planning software demonstrate any significant difference in maximum cord dosage than the original plan. Conclusions: The timing of symptomatology related to chemotherapy administration is consistent with radiation recall myelitis, which has yet to be reported following SBRT. Given the potentially disastrous consequences of myelitis, patients with metastatic disease previously treated with spine SBRT may be susceptible to developing myelitis if treated with paclitaxel chemotherapy.

Original languageEnglish (US)
Pages (from-to)331-334
Number of pages4
JournalJournal of Radiosurgery and SBRT
Volume5
Issue number4
StatePublished - Jan 1 2018

Fingerprint

Myelitis
Radiosurgery
Paclitaxel
Radiation
Drug Therapy
Spine
Hypesthesia
Thorax
Neoplasm Metastasis
Intractable Pain
Back Pain
Standard of Care
Lower Extremity
Edema
Leg
Spinal Cord
Urinary Bladder
Software
Steroids
Breast Neoplasms

Keywords

  • Metastatic breast cancer
  • Paclitaxel
  • Radiation recall myelitis
  • Spine SBRT

ASJC Scopus subject areas

  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Radiation recall myelitis following paclitaxel chemotherapy : The first reported case. / McClelland, Shearwood; Cooper, Paul H.; Acheson, Anupama K.; Ciporen, Jeremy; Jaboin, Jerry; Mitin, Timur.

In: Journal of Radiosurgery and SBRT, Vol. 5, No. 4, 01.01.2018, p. 331-334.

Research output: Contribution to journalArticle

@article{70734beafe634e0ea7a836d75e095cec,
title = "Radiation recall myelitis following paclitaxel chemotherapy: The first reported case",
abstract = "Introduction: Stereotactic body radiotherapy (SBRT) of the spine has become an increasingly utilized modality in the United States, most commonly for metastatic disease (McClelland et al., 2017). Spinal SBRT in patients with spinal instrumentation has been sparsely examined. We report a patient who developed myelitis following spinal SBRT to a region with existing hardware. Methods: A 55-year-old woman with Stage IV breast cancer developed a T4 vertebral body metastasis and underwent tumor debulking with posteriorly instrumented T3-T5 fusion. Postoperatively she proceeded with SBRT to the T3-T5 vertebral bodies, receiving 30 Gy in 6 Gy/fraction. Seven months later, she required paclitaxel chemotherapy (80 mg/m2 per cycle) for new liver metastases. Results: Eight months following spine SBRT, four weeks after having started chemotherapy she developed intractable back pain and right lower extremity numbness which improved upon receiving steroids for weekly chemotherapy; the numbness subsequently spread to her left leg. Thoracic spine MRI revealed a 1.7 cm ovoid focus of T4-T5 spinal cord enhancement with extensive surrounding cord edema extending superiorly to C6-C7, consistent with radiation myelitis. Hyperbaric oxygen moderately improved her symptoms; fortunately, she never developed motor symptomatology or bowel/bladder dysfunction. Thorough re-evaluation of the original thoracic spine SBRT plan revealed no deviations from the standard of care, nor did re-planning with alternate treatment planning software demonstrate any significant difference in maximum cord dosage than the original plan. Conclusions: The timing of symptomatology related to chemotherapy administration is consistent with radiation recall myelitis, which has yet to be reported following SBRT. Given the potentially disastrous consequences of myelitis, patients with metastatic disease previously treated with spine SBRT may be susceptible to developing myelitis if treated with paclitaxel chemotherapy.",
keywords = "Metastatic breast cancer, Paclitaxel, Radiation recall myelitis, Spine SBRT",
author = "Shearwood McClelland and Cooper, {Paul H.} and Acheson, {Anupama K.} and Jeremy Ciporen and Jerry Jaboin and Timur Mitin",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
volume = "5",
pages = "331--334",
journal = "Journal of Radiosurgery and SBRT",
issn = "2156-4639",
publisher = "Old City Publishing",
number = "4",

}

TY - JOUR

T1 - Radiation recall myelitis following paclitaxel chemotherapy

T2 - The first reported case

AU - McClelland, Shearwood

AU - Cooper, Paul H.

AU - Acheson, Anupama K.

AU - Ciporen, Jeremy

AU - Jaboin, Jerry

AU - Mitin, Timur

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Stereotactic body radiotherapy (SBRT) of the spine has become an increasingly utilized modality in the United States, most commonly for metastatic disease (McClelland et al., 2017). Spinal SBRT in patients with spinal instrumentation has been sparsely examined. We report a patient who developed myelitis following spinal SBRT to a region with existing hardware. Methods: A 55-year-old woman with Stage IV breast cancer developed a T4 vertebral body metastasis and underwent tumor debulking with posteriorly instrumented T3-T5 fusion. Postoperatively she proceeded with SBRT to the T3-T5 vertebral bodies, receiving 30 Gy in 6 Gy/fraction. Seven months later, she required paclitaxel chemotherapy (80 mg/m2 per cycle) for new liver metastases. Results: Eight months following spine SBRT, four weeks after having started chemotherapy she developed intractable back pain and right lower extremity numbness which improved upon receiving steroids for weekly chemotherapy; the numbness subsequently spread to her left leg. Thoracic spine MRI revealed a 1.7 cm ovoid focus of T4-T5 spinal cord enhancement with extensive surrounding cord edema extending superiorly to C6-C7, consistent with radiation myelitis. Hyperbaric oxygen moderately improved her symptoms; fortunately, she never developed motor symptomatology or bowel/bladder dysfunction. Thorough re-evaluation of the original thoracic spine SBRT plan revealed no deviations from the standard of care, nor did re-planning with alternate treatment planning software demonstrate any significant difference in maximum cord dosage than the original plan. Conclusions: The timing of symptomatology related to chemotherapy administration is consistent with radiation recall myelitis, which has yet to be reported following SBRT. Given the potentially disastrous consequences of myelitis, patients with metastatic disease previously treated with spine SBRT may be susceptible to developing myelitis if treated with paclitaxel chemotherapy.

AB - Introduction: Stereotactic body radiotherapy (SBRT) of the spine has become an increasingly utilized modality in the United States, most commonly for metastatic disease (McClelland et al., 2017). Spinal SBRT in patients with spinal instrumentation has been sparsely examined. We report a patient who developed myelitis following spinal SBRT to a region with existing hardware. Methods: A 55-year-old woman with Stage IV breast cancer developed a T4 vertebral body metastasis and underwent tumor debulking with posteriorly instrumented T3-T5 fusion. Postoperatively she proceeded with SBRT to the T3-T5 vertebral bodies, receiving 30 Gy in 6 Gy/fraction. Seven months later, she required paclitaxel chemotherapy (80 mg/m2 per cycle) for new liver metastases. Results: Eight months following spine SBRT, four weeks after having started chemotherapy she developed intractable back pain and right lower extremity numbness which improved upon receiving steroids for weekly chemotherapy; the numbness subsequently spread to her left leg. Thoracic spine MRI revealed a 1.7 cm ovoid focus of T4-T5 spinal cord enhancement with extensive surrounding cord edema extending superiorly to C6-C7, consistent with radiation myelitis. Hyperbaric oxygen moderately improved her symptoms; fortunately, she never developed motor symptomatology or bowel/bladder dysfunction. Thorough re-evaluation of the original thoracic spine SBRT plan revealed no deviations from the standard of care, nor did re-planning with alternate treatment planning software demonstrate any significant difference in maximum cord dosage than the original plan. Conclusions: The timing of symptomatology related to chemotherapy administration is consistent with radiation recall myelitis, which has yet to be reported following SBRT. Given the potentially disastrous consequences of myelitis, patients with metastatic disease previously treated with spine SBRT may be susceptible to developing myelitis if treated with paclitaxel chemotherapy.

KW - Metastatic breast cancer

KW - Paclitaxel

KW - Radiation recall myelitis

KW - Spine SBRT

UR - http://www.scopus.com/inward/record.url?scp=85056704237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056704237&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 331

EP - 334

JO - Journal of Radiosurgery and SBRT

JF - Journal of Radiosurgery and SBRT

SN - 2156-4639

IS - 4

ER -